Edith Cowan University

Research Online
Research outputs 2022 to 2026
7-1-2022

BAP1 loss by immunohistochemistry predicts improved survival
to first-line platinum and pemetrexed chemotherapy for patients
with pleural mesothelioma: A validation study
Amber Louw
Edith Cowan University

Vasiliki Panou
Weronika Maria Szejniuk
Christos Meristoudis
Siaw Ming Chai

See next page for additional authors

Follow this and additional works at: https://ro.ecu.edu.au/ecuworks2022-2026
Part of the Oncology Commons
10.1016/j.jtho.2022.04.008
Louw, A., Panou, V., Szejniuk, W. M., Meristoudis, C., Chai, S. M., van Vliet, C., ... & Røe, O. D. (2022). BAP1 Loss by
immunohistochemistry predicts improved survival to first-line platinum and pemetrexed chemotherapy for patients
with pleural mesothelioma: A validation study. Journal of Thoracic Oncology, 17(7), p.921-930. https://doi.org/
10.1016/j.jtho.2022.04.008
This Journal Article is posted at Research Online.
https://ro.ecu.edu.au/ecuworks2022-2026/920

Authors
Amber Louw, Vasiliki Panou, Weronika Maria Szejniuk, Christos Meristoudis, Siaw Ming Chai, Chris van
Vliet, Y. C.Gary Lee, Ian M. Dick, Tina Firth, Louise Andersen Lynggaard, Azadeh Birbaneh Asghari, Mogens
Vyberg, Johnni Hansen, Jenette Creaney, and Oluf Dimitri Røe

This journal article is available at Research Online: https://ro.ecu.edu.au/ecuworks2022-2026/920

ORIGINAL ARTICLE

BAP1 Loss by Immunohistochemistry Predicts
Improved Survival to First-Line Platinum and
Pemetrexed Chemotherapy for Patients With
Pleural Mesothelioma: A Validation Study
Amber Louw, BSc, M.B.B.S.,a,b,c,d Vasiliki Panou, MD, PhD,e,f,g
Weronika Maria Szejniuk, MD, PhD,h,i Christos Meristoudis, MD,j
Siaw Ming Chai, M.B.B.S., MSc,a Chris van Vliet, M.B.B.S.,a
Y. C. Gary Lee, MbChB., PhD,c,k,l Ian M. Dick, PhD,d Tina Firth, PhD,c,d
Louise Andersen Lynggaard, MD,j Azadeh Birbaneh Asghari, MD,j
Mogens Vyberg, MD, PhD,m Johnni Hansen, PhD,n Jenette Creaney, PhD,c,d,k,*
Oluf Dimitri Røe, MD, PhDh,i,o,p
a

Department of Anatomical Pathology, PathWest Laboratory Medicine, QEII Medical Centre, Perth, Australia
School of Medical and Health Sciences, Edith Cowan University, Perth, Australia
c
Institute for Respiratory Health, Perth, Australia
d
National Centre for Asbestos Related Disease, University of Western Australia, Perth, Australia
e
Department of Respiratory Medicine, Odense University Hospital, Odense, Denmark
f
Department of Respiratory Diseases, Aalborg University Hospital, Aalborg, Denmark
g
Department of Clinical Research, University of Southern Denmark, Odense, Denmark
h
Department of Oncology & Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark
i
Department of Clinical Medicine, Aalborg University Hospital, Aalborg, Denmark
j
Institute of Pathology, Aalborg University Hospital, Aalborg, Denmark
k
Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, Australia
l
Medical School, University of Western Australia, Perth, Australia
m
Center for RNA Medicine, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark
n
Danish Cancer Society, Research Center, Copenhagen, Denmark
o
Department of Oncology, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway
p
Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
b

Received 13 February 2022; revised 9 April 2022; accepted 15 April 2022
Available online - 27 April 2022

ABSTRACT
Introduction: Pleural mesothelioma (PM) is an aggressive
malignancy with no identiﬁed predictive biomarkers. We
assessed whether tumor BAP1 status is a predictive
biomarker for survival in patients receiving ﬁrst-line combination platinum and pemetrexed therapy.
Methods: PM cases (n ¼ 114) from Aalborg, Denmark, were
stained for BAP1 on tissue microarrays. Demographic,
clinical, and survival data were extracted from registries
and medical records. Surgical cases were excluded. BAP1
status was associated with overall survival (OS) by Cox
regression and Kaplan-Meier methods. Results were validated
in an independent cohort from Perth, Australia (n ¼ 234).
Results: BAP1 loss was found in 62% and 60.3% of all
Danish and Australian samples, respectively. BAP1 loss was
an independent predictor of OS in multivariate analyses
corrected for histological subtype, performance status, age,

sex, and treatment (hazard ratio ¼ 2.49, p < 0.001, and
1.48, p ¼ 0.01, respectively). First-line platinum and
pemetrexed-treated patients with BAP1 loss had signiﬁcantly longer median survival than those with retained
BAP1 in both the Danish (20.1 versus 7.3 mo, p < 0.001)
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and Australian cohorts (19.6 versus 11.1 mo, p < 0.01).
Survival in patients with BAP1 retained and treated with
platinum and pemetrexed was similar as in those with best
supportive care. There was a higher OS in patients with best
supportive care with BAP1 loss, but it was signiﬁcant only
in the Australian cohort (16.8 versus 8.3 mo, p < 0.01).
Conclusions: BAP1 is a predictive biomarker for survival
after ﬁrst-line combination platinum and pemetrexed
chemotherapy and a potential prognostic marker in PM.
BAP1 in tumor is a promising clinical tool for treatment
stratiﬁcation.
 2022 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. This is an open access
article under the CC BY license (http://creativecommons.
org/licenses/by/4.0/).
Keywords: Pleural mesothelioma; BAP1; Chemotherapy;
Predictive biomarkers; Pemetrexed

Introduction
Mesothelioma is a malignancy of the serosal linings,
involving the pleural cavity in more than 70% of cases.1
The disease is most often caused by asbestos inhalation
resulting in malignancy decades after exposure.1,2
Pleural mesothelioma (PM) is aggressive, with treatment generally being palliative and overall survival (OS)
from diagnosis less than 12 months.3,4
Combination chemotherapy with a platinum agent
and pemetrexed has been the standard-of-care ﬁrst-line
treatment for patients with PM for almost two decades.
This treatment has a 40% response rate, extending
survival over platinum therapy alone by 2 to 3 months.5
To date, no clinically meaningful predictive biomarkers
have been established.6 Recently, dual immunotherapy
with ipilimumab and nivolumab has been approved as a
ﬁrst-line treatment in PM, revealing an increase in OS of
18.1 versus 14.1 months in comparison to platinum and
pemetrexed. The overall response rate was 40%, with a
more modest effect in the epithelioid subtype.7 Because
immunotherapy is a relatively costly treatment, it is
likely that chemotherapy will continue to be used in the
years to come, either in the ﬁrst- or second-line setting.
Therefore, predictive biomarkers remain relevant for
this treatment modality and would provide a way to aid in
targeting the correct population and avoid overtreatment.
BAP1 is a multifunctional tumor suppressor that is
expressed in all normal mesothelial cells. Nevertheless, it
is frequently altered in PM, with abnormalities observed
at the genetic, epigenetic, and protein levels.8–11 BAP1
plays a role in DNA repair and other mechanisms that may
affect response to platinum and pemetrexed treatment.12
BAP1 immunohistochemistry (IHC) is considered a
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reliable method of determining BAP1 status, indicating
biallelic loss of functional protein, with BAP1 loss occurring in approximately 60% of tumors.4,9,13–19 Less than
5% of patients with PM harbor germline abnormalities in
BAP1; these patients were found to have longer survival
than those without germline mutations and to have
beneﬁt from platinum-based therapy.20–24
Few studies have speciﬁcally evaluated the association of BAP1 IHC status with platinum and pemetrexed
treatment.14,25,26 On the basis of the biological function
of BAP1 and longer survival in treated patients with
BAP1 germline mutation, we postulated that loss of
BAP1 in the tumor may predict survival after platinum
and pemetrexed treatment in a general PM cohort.
The primary aim of this study was to investigate
whether patients with PM with tumors harboring BAP1
loss as determined by IHC have improved survival to a ﬁrstline chemotherapeutic regimen of platinum and pemetrexed. The secondary aim was to investigate the prognostic role of BAP1 loss in untreated patients with PM.
These associations were evaluated in a Danish cohort of
patients, before validating the ﬁndings in a larger Australian cohort. This is the ﬁrst independently validated study
to assess the relationship between BAP1 status and survival in treated and untreated patients with PM.

Materials and Methods
Study Cohorts
Danish Cohort. Patients diagnosed with having PM between 1976 and 2018 were identiﬁed at the Institute of
Pathology, Aalborg University Hospital, Denmark. Pathology specimens, both biopsy and ﬂuid, were conﬁrmed
as PM by two independent pathologists, according to international guidelines. From eligible biopsies, tissue
microarrays (TMAs) were created. TMAs were constructed semiautomatically using three manually premarked representative areas (three cores) of each tumor,
with a punch diameter of 2 mm. Construction was performed using the TMA Grand Master (3DHistech Ltd.,
Hungary). BAP1 IHC was performed on 3-mm formalinﬁxed, parafﬁn-embedded sections using the anti-BAP1
C4 mouse monoclonal antibody (Santa Cruz Biotechnology) at a dilution of 1:50 using the OptiView DAB IHC
Detection Kit (Ventana) on the Ventana BenchMark
ULTRA platform (Roche Diagnostics). Any nuclear positivity was considered retained staining; stromal cells and
lymphocytes were used as a positive internal control. The
individuals performing and interpreting the stain were
blinded as to the clinical outcome of the patients.
This project was approved by the Regional Ethical
Committee of North Jutland, Denmark (registration
number N-20140032) and the Danish Protection Data
Agency (number 2008-58-0028).
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Australian Cohort. PM cases diagnosed at PathWest
Laboratory Medicine, QEII Medical Centre, Perth, Western Australia, between 2010 and 2018 were identiﬁed.
Cases where patients had given consent for research
were reviewed. All cases were conﬁrmed as PM by pathologists according to diagnostic criteria current to the
time period. This includes diagnosis based on review of
cytologic specimens, where no histology sample was
available. BAP1 IHC was performed as previously
described.27 Brieﬂy, BAP1 IHC was performed on 4-mm
formalin-ﬁxed, parafﬁn-embedded sections using the
same antibody clone at the same dilution as mentioned
previously using the UltraView DAB Detection Kit on the
same platform. The individuals performing and interpreting the stain were blinded as to the clinical outcome
of the patients.
This project was approved by the Sir Charles Gairdner
and Osborne Park Health Care Group Human Research
Ethics Committee, number 2005-038 (RGS0000001517).

Clinical Information
For both the Danish and Australian cohorts, the
following information was retrospectively collected from
patient records and hospital databases: demographic
information (age, sex), performance status (using the
Eastern Cooperative Oncology Group Performance Status
[ECOG PS]), PM subtype (on histology), treatment information, and survival data (date of death or date of
censor). Patient management was decided by the treating clinician as part of routine care. Patients who underwent surgical management were excluded from the
study. For classiﬁcation purposes, the subtype was
categorized as follows: epithelioid PM, sarcomatoid PM,
biphasic PM, and PM diagnosed by cytology only (with
no histologic conﬁrmation). Treatment was categorized
as either ﬁrst-line platinum and pemetrexed or other
systemic antineoplastic ﬁrst-line therapy. The latter
subgroup comprised a heterogeneous mixture of patients who received various treatments appropriate at
the time or as part of a clinical trial; although this group
was included in the OS analysis, they were not included
in the platinum and pemetrexed analysis. Second-line or
subsequent treatments received were recorded but not
included in the analysis owing to their diverse nature.
Patients who did not receive any systemic antineoplastic
or novel therapies were categorized as having received
best supportive care (BSC). Cases with incomplete
treatment histories or missing follow-up data were
excluded.

Statistical Analysis
Patients of both cohorts were stratiﬁed into two
groups on the basis of BAP1 status, either BAP1 retained
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or lost. Primary outcome was OS deﬁned as time elapsed
between the date of PM diagnosis to the date of death or
last follow-up. Difference in OS between groups was
estimated by the Kaplan-Meier method using a log-rank
test. Univariate Cox regression analysis was performed
to compare the risk of death between the groups.
Multivariate Cox regression analysis was performed with
adjustment for age, sex, ECOG PS, histopathologic subtype, and treatment. Individuals with missing values
were excluded from the analysis. For statistical purposes, age was categorized as less than or equal to 70
years and more than 70 years, ECOG PS as less than or
equal to 1 and more than or equal to 2, whereas subtype
was classiﬁed as epithelioid and nonepithelioid. t test or
Fisher’s exact tests were used to evaluate variances in
clinical factors of patients between the groups, as
appropriate. Tests of statistical signiﬁcance were two
sided, and p values less than 0.05 were considered statistically signiﬁcant. Analyses were performed using the
STATA statistical software program (STATA version
16.0; StataCorp., College Station, TX).

Results
Danish and Australian Cohorts
In the Danish cohort, a total of 149 cases diagnosed
with having PM were identiﬁed during 1983 to 2018,
with 114 cases meeting the inclusion criteria
(Supplementary Fig. 1A). There were 42 who received
platinum and pemetrexed in the ﬁrst-line setting and 49
who received BSC. The median number of cycles of
platinum and pemetrexed received in the Danish cohort
was three (mean 3.48 ± 1.3 cycles). All participants were
deceased at the time of the study (Table 1). Most of the
tumors had loss of BAP1 (62.3%), and this was most
common in the epithelioid subtype (67%) (Table 2).
In the Australian cohort, there were 262 cases
available during the 8-year time period evaluated, with a
total of 234 cases meeting the speciﬁed criteria
(Supplementary Fig. 1B). Platinum and pemetrexed was
administered to 108 patients, whereas 96 received BSC.
A median of four cycles of platinum and pemetrexed was
received in this cohort (mean 3.98 ± 1.7 cycles). Nine
patients were alive at the end of the follow-up period;
median follow-up for these patients was 39 months
(range: 31–75 mo). In comparison to the Danish cohort,
this cohort was signiﬁcantly older at diagnosis, had a
better performance status, had a lower frequency of the
biphasic histologic subtype, and 41% were diagnosed by
cytology (Table 1). BAP1 loss was detected in most of the
tumors (60.7%) (Table 1).
Median survival from diagnosis was 11 and 14.3
months in the Danish and Australian cohorts, respectively (Table 1). Median survival was longest in the
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Table 1. Comparison of the Demographic and Clinical Characteristics in the Danish and Australian Cohorts
Characteristics

Danish Cohort (n ¼ 114)

Australian Cohort (n ¼ 234)

p Value

Age, y, median (95% CI)
Sex, male, n (%)
Mesothelioma subtype
Epithelioid
Nonepithelioid
Epithelioid, n (%)
Sarcomatoid, n (%)
Biphasic, n (%)
Cytology, n (%)
Not classiﬁed, n (%)
ECOG PS, n (%)
0–1
2–4
Missing
Lines of treatment received, n (%)
One
Two
Three or more
Treatment, n (%)
BSC
Platinum and pemetrexedd
Other systemic treatmente
BAP1
Retained
Lost
Survival, mo, median (95% CI)

68.4 (66–72)
102 (89.4)

72.3 (70.5–74)
203 (86.8)

0.02a
0.61b
<0.0001c

55
55
55 (48.2)
12 (10.5)
43 (37.7)
Nil
4 (3.5)

181
53
85 (36.3)
23 (9.8)
30 (12.8)
96 (41.0)
Nil
0.05b

82 (71.9)
22 (19.3)
10 (8.8)

201 (85.9)
29 (12.4)
4 (1.7)

19 (16)
29 (25)
17 (15)

67 (29)
32 (14)
39 (16)

49 (42.9)
42 (36.8)
23 (20.2)

96 (41.0)
108 (46.2)
30 (12.8)

0.0047b

0.31f

0.448b
43 (37.7)
71 (62.3)
11.3 (8.5–14.2)

92 (39.3)
142 (60.7)
14.3 (12.5–17)

0.001g

a

Difference between groups determined by unpaired t test.
Difference between groups determined by Fisher’s exact test or chi-square; missing data excluded from analysis.
Difference between epithelioid (including cases diagnosed by cytology) and nonepithelioid (biphasic and sarcomatoid) determined by Fisher’s exact test.
d
Four patients went on to receive pembrolizumab in subsequent treatment.
e
Three patients received pembrolizumab.
f
Difference between BSC and platinum and pemetrexed treatment groups determined by Fisher’s exact test.
g
Difference between groups determined by log-rank test.
BSC, basic supportive care; CI, conﬁdence interval; ECOG PS, Eastern Cooperative Oncology Group Performance Status.
b
c

epithelioid in comparison to the nonepithelioid subgroup
in both cohorts (12.9 versus 6.9 mo, p < 0.05, and 17.9
versus 8.3 mo, p < 0.0001, respectively). Patients who
received BSC had signiﬁcantly higher risk of death
compared with those receiving platinum and pemetrexed treatment in the ﬁrst line, in both cohorts (hazard
ratio ¼ 2.84, p < 0.001, and 1.46, p ¼ 0.012,

Table 2. Rates of BAP1 Loss by Mesothelioma Subtype
Mesothelioma
Subtype

Danish Cohort
BAP1 Loss n (%)

Australian Cohort
BAP1 Loss n (%)

Epithelioid
mesothelioma
Biphasic
mesothelioma
Sarcomatoid
mesothelioma
Cytology diagnosis
of mesothelioma
Not classiﬁed

37/55 (67)

58/85 (68.2)

27/43 (63)

6/23 (26.1)

4/12 (33)

4/30 (13.3)

—

74/96 (77.1)

3/4 (75)

—

respectively) on multivariate analysis (Table 3). Not
unexpectedly, those patients in the Australian cohort
who received less than four cycles of treatment survived
for a signiﬁcantly shorter period of time than those who
received four to six cycles (median survival 314 d versus
625 d, p < 0.0001). In the Danish cohort, only four patients had less than three cycles of therapy.

BAP1 Status Is Associated With Survival in
Platinum and Pemetrexed-Treated Patients
Survival analysis of the total cohort revealed a signiﬁcant survival advantage in those with BAP1 loss in
tumors, in both populations (14.2 versus 6.3 mo, p <
0.0001, and 18.9 versus 10.8 mo, p < 0.001, respectively) (Fig. 1A and B). Median survival in the Danish
patients treated with platinum and pemetrexed in the
ﬁrst line was signiﬁcantly longer in those with BAP1 loss
compared with those with retained staining (20.2 versus
7.3 mo, p < 0.001), and this was validated in the
Australian cohort (19.6 versus 11.1 mo, p < 0.01)
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Table 3. Variables Associated With Overall Survival in the Danish and Australian Cohorts on Univariate and Multivariate Cox
Regression Analyses
Variable
Danish cohort
BAP1 retained
Best supportive care
ECOG PS 2
Nonepithelioid mesothelioma
Age >70 y
Female sex
Australian cohort
BAP1 retained
Best supportive care
ECOG PS  2
Nonepithelioid mesothelioma
Age >70 y
Female sex

Univariate Analysis (HR, 95% CI, p value)

Multivariate Analysis (HR, 95% CI, p value)

2.3, 1.53–3.43, p < 0.001
1.77, 1.16–2.7, p [ 0.008a
1.93, 1.17–3.19, p [ 0.011b
2.82, 1.74–4.59, p < 0.001
1.4, 0.95–2.07, p ¼ 0.91
1.23, 0.83–1.80, p ¼ 0.304
1.42, 0.79–2.54, p ¼ 0.242

2.49, 1.54–4.0, p < 0.001
2.84, 1.61–5, p < 0.001a
5.13, 2.45–10.75, p < 0.001b
1.65, 0.96–2.83, p ¼ 0.69
2.1, 1.27–3.47, p [ 0.004
1.8, 1.09–2.97, p [ 0.023
1.18, 0.62–2.23, p ¼ 0.618

1.90, 1.44–2.50, p < 0.001
1.59, 1.2–2.11, p < 0.001a
2.2, 1.43–3.38, p < 0.001b
2.19, 1.48–3.25, p < 0.001
2.52, 1.82–3.48, p < 0.001
1.63, 1.25–2.14, p < 0.001
0.90, 0.62–1.32, p ¼ 0.59

1.48, 1.099–2, p [ 0.01
1.46, 1.09–1.96, p [ 0.012a
1.65, 1.04–2.66, p [ 0.035b
2.03, 1.35–3.07, p [ 0.001
2.26, 1.59–3.23, p < 0.001
1.27, 0.94–1.72, p ¼ 0.13
1.17, 0.79–1.73, p ¼ 0.43

All statistically signiﬁcant results are highlighted in bold.
a
Platinum and pemetrexed treatment.
b
Other treatment.
CI, conﬁdence interval; ECOG PS, Eastern Cooperative Oncology Group Performance Status; HR, hazard ratio

(Fig. 1C and D). Importantly, median survival of patients
with retained BAP1 after platinum and pemetrexed
treatment was no different than that of the BSC group as
a whole (Fig. 2A and B).
Survival analysis of the Danish BSC group did not
reveal a signiﬁcant association of BAP1 status and OS
(BAP1 loss 6.2 versus retained 3.8 mo, p ¼ 0.12), but it
was signiﬁcant in the Australian cohort (BAP1 loss 16.8
versus retained 8.3 mo, p < 0.01) (Fig. 1E and F). BAP1
loss was positively predictive of survival in those diagnosed with having epithelioid disease but also nonepithelioid in both cohorts (Supplementary Fig. 2A–D).
Posthoc analysis was performed and determined that
survival outcomes, relative to BAP1 status, did not differ
between cases classed as predominantly epithelioid, on
the basis of histology or cytology. The group diagnosed
on the basis of cytologic samples only had a higher rate
of BAP1 loss (77%) than the epithelioid group (68%),
although this was not signiﬁcantly different (p ¼ 0.24).
There was no signiﬁcant difference in survival by BAP1
status between cases diagnosed on the basis of histology
or cytology (Supplementary Fig. 3A and B).

Discussion
To date, no predictive biomarkers for survival after
primary chemotherapy in PM have been identiﬁed. In
our study, we reveal and validate that tumor BAP1 loss
predicts a more than 8-month increase in OS in patients
treated with platinum and pemetrexed in the ﬁrst-line
setting, in comparison to those with retained staining.
In contrast, patients with retained BAP1 who received

dual chemotherapy had a similar median OS to those
who received no active treatment. The results imply that
all PM tumors should be stained for BAP1, and caution
should be used when considering this chemotherapy
doublet in patients with PM with BAP1-retained tumor.
Platinum and pemetrexed has been the primary ﬁrstline treatment of patients with PM considered ﬁt for
chemotherapy since the pivotal work of Vogelzang et al.5
in 2003, with surgery offered to a few patients. This is
reﬂected in our Danish and Australian cohorts, where
less than 10% and 5% underwent surgery, respectively.
In the cohorts, 34% and 41%, respectively, of the patients received BSC only owing to their frailty, patient
preference, comorbidities, advanced disease, or a combination of these factors.
The main rationale in using a predictive biomarker is
to allow targeting of the correct population and to avoid
overtreatment. In mesothelioma, such a marker has not
yet been identiﬁed. Tumor subtype is perhaps thus far
the most consistent prognostic indicator, though it is not
regarded as a predictive biomarker for chemotherapy.
Previous studies attempting to identify biomarkers predictive of response to platinum and pemetrexed in PM
have focused on candidates involved in drug transport,
metabolism, and DNA repair, such as thymidylate synthase and excision repair cross complementing 1.28
Despite many promising single-center studies, a lack of
robust validation and difﬁculties in standardizing
detection methods have meant that no such markers
have yet been incorporated in the clinical practice.
BAP1 is located in 3p21, and it is one of the most
frequently altered genes in PM.14,29,30 Recent studies
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Figure 1. Kaplan-Meier survival curves for the Danish cohort (left panel) and Aus cohort (right panel) dichotomized by BAP1
status. (A and B) The total cohort; (C and D) the cohort that received ﬁrst-line Plat and Pem; (E and F) the cohort that
received BSC. Aus, Australian; BAP1 –ve, loss of nuclear staining; BAP1 þve, retained nuclear staining; BSC, best supportive
care; Pem, pemetrexed; Plat, platinum.

have revealed that loss of 3p21 or mutation is an
early event in evolution of PM.31 BAP1 encodes a deubiquitinase involved in a range of cellular processes,
including homologous recombination, DNA repair, cell
cycle
control,
chromatin
modiﬁcation,
and
apoptosis.12,32–34 The exact mechanism by which BAP1
loss provides a survival advantage to chemotherapy-

treated patients is not entirely clear. The most plausible mechanism is that of a hampered DNA repair
system unable to repair platinum-induced DNA damage, increasing cancer cell sensitivity, leading to
apoptosis.34 Similar ﬁndings have been observed in
patients with BRCA1 or 2-deﬁcient breast and ovarian
malignancies post-platinum therapy.35,36
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Figure 2. Kaplan-Meier curves for the (A) Danish and (B)
Australian cohorts, comparing survival in those who had BSC
(green) and those who received ﬁrst-line Plat and Pem and
had retained BAP1 staining (red). BAP1 þve, BAP1 retained
nuclear staining; BSC, best supportive care; Plat and Pem,
platinum and pemetrexed.

There has been no large-scale assessment of the
relationship between survival after standard therapy
and BAP1 status as assessed by IHC. Many studies have
evaluated the correlation of BAP1 status by IHC and
prognosis and have had mixed results, although most
have found no signiﬁcant association with survival after
adjusting for known prognostic indicators.4,16,18,25,37–40
This lack of consistency may be due to many factors,
including small number of patients, lack of validation,
heterogeneity in patient selection, study size, patient
management, and the adjustment, or lack thereof, within
these studies for known prognostic indicators. In this
study, we have revealed that BAP1 is a predictive marker
in platinum and pemetrexed, nonsurgical PM patients in
both the Danish and Australian cohorts, independent of
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other prognostic markers such as age, sex, ECOG PS, and
histological subtype. The difference in survival on the
basis of BAP1 status was more than 8 months (20.1
versus 7.3 mo, p < 0.001, and 19.6 versus 11.1 months, p
< 0.01, in Aalborg and Perth, respectively), which is
clinically meaningful, given the normally poor survival
time.
Therefore, this is the ﬁrst validated study to assess
the association between BAP1 status and survival after
ﬁrst-line platinum and pemetrexed treatment. Importantly, we have also revealed the relative lack of effect of
chemotherapy in those with retained BAP1 in tumors, by
comparing this group with the BSC group in each cohort.
The Kaplan-Meier curves of the chemotherapy-treated
patients with BAP1 retained are similar to the BSC
curves and reveal that this is clearly a subgroup of patients who minimally beneﬁt from combined platinum
and pemetrexed chemotherapy (Fig. 2).
As the distinction between prognostic and predictive
biomarkers can be ambiguous, we performed subgroup
analysis comparing the BSC patients in the two cohorts.
Using this approach, differing results were observed,
with a signiﬁcant OS difference in BAP1 loss patients in
the Australian, but not in the Danish, cohort. Although
this heterogeneous ﬁnding occurring in our single study
may be due to small sample numbers, it is nevertheless
reﬂective of the wider mixed results of BAP1 prognostic
value in the literature.
After the results of the CheckMate 743 study that
revealed OS beneﬁt of immunotherapy compared with
platinum and pemetrexed as front-line therapy, one can
question the clinical value of BAP1 as a biomarker.7
Although dual immunotherapy will likely be the standard of care, there is a fact that in patients with
epithelioid mesothelioma the median survival difference
with dual immunotherapy is 2.2 months whereas in the
nonepithelioid it is almost 9.3 months. Thus, there is no
doubt that dual immunotherapy is the best option in
nonepithelioid, but the possible fatal side effects and the
high cost may push clinicians to choose chemotherapy in
the epithelioid subtype. In Denmark, the combination of
ipilimumab and nivolumab has recently been approved
in the ﬁrst-line treatment exclusively for patients with
nonepithelioid disease, and consequently platinumbased combination with pemetrexed remains the ﬁrstline treatment for most patients with inoperable PM.
On the basis of our results, it is tempting to treat patients
with BAP1 loss and epithelioid subtype with pemetrexed
and platinum as they have more than 6 months longer
survival compared with those with BAP1 epithelioid
with retained BAP1 in both cohorts (Supplementary
Fig. 2). The dual immunotherapy could be then preserved as a second-line option in the BAP1 loss epithelioid subgroup. Because we have a lack of predictive
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biomarkers for immunotherapy in epithelioid PM, BAP1
may help clinicians decide a more tailored treatment
algorithm.
This study has a number of strengths and limitations.
The two independent cohorts in two countries with welldeﬁned clinical and re-evaluated pathologic data is a
strength, including the relatively large number of BSCtreated patients. Patients receiving surgery were
excluded from the cohorts, and patients receiving other
ﬁrst-line therapies, including novel therapies as part of
clinical trials, were excluded from the principal predictive analysis. Although this has likely resulted in a
number of younger patients with a lower ECOG PS being
excluded from our study, this was done to allow more
speciﬁc assessment of the association between ﬁrst-line
platinum and pemetrexed and BAP1 status. Interestingly,
there was a difference in OS observed between the two
cohorts. This may be due to several factors. First, twothirds of the Danish cohort were diagnosed and treated
before 2010, which was the start of patient inclusion for
the Australian cohort. Furthermore, at the Danish site,
any cytologic diagnosis of PM required biopsy conﬁrmation, whereas at the Australian site, PM diagnosis by
cytology only is commonplace. In addition to a diagnostic
lead-time effect, this may affect histologic subtype proportions as we cannot exclude that some patients with a
cytologic diagnosis have biphasic disease. Importantly,
despite differences that may occur owing to different
diagnostic or treatment traditions and time periods, the
main results were recapitulated in both cohorts. Another
limitation was the lack of availability of radiological
response data. Although such data would be informative,
it is known to be a surrogate for OS in PM and therefore
should reveal similar ﬁndings. Our analyses did not account for subsequent treatment beyond the ﬁrst-line
setting; several patients received subsequent lines of
various chemotherapies and in the Australian cohort a
small number received immunotherapy. Nevertheless, to
date, there is no phase 3 study revealing any survival
advantage of second-line chemotherapy; thus, the effect
on OS is expected to be due to the platinum and pemetrexed treatment.
BAP1 status by IHC is a simple investigation that
captures loss of BAP1 protein expression occurring at
multiple levels. If validated in a prospective series,
BAP1 is a readily translatable biomarker as IHC is
routinely used in pathology laboratories around the
world as part of mesothelioma diagnostic workup and
can therefore be easily adapted for use in triaging
patients.
In summary, we present evidence in two independent
PM cohorts that BAP1 status can predict survival after
the standard ﬁrst-line platinum and pemetrexed
chemotherapy regimen. This may have substantial
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implications for patient management if conﬁrmed in a
prospective cohort as this result suggests that BAP1retained patients receiving active chemotherapy derive
limited survival beneﬁt and likely endure treatmentassociated side effects. This subgroup could therefore
be considered for other types of treatment. This predictive marker can be a tool, alongside prognostic variables, such as subtype and performance status, to
determine the best treatment options for patients and
may represent a move toward more personalized treatment in this aggressive disease. Further prospective
trials are needed to validate these ﬁndings.
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